← Issue №4/ week of Jul 26, 2026/Hepatology

Implications of new obesity definitions in the classification and outcomes of patients with MASLD.

From GI Signals issue №4: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology prospective cohort · n=12,583 · Jul 27, 2026 · Hepatology · IF 18.0

Implications of new obesity definitions in the classification and outcomes of patients with MASLD.

New evidenceMASLDepidemiologyobesity
Clinical takeawayNo clinical action yet: new obesity definitions did not improve liver risk prediction over BMI in MASLD. Continue using BMI for risk stratification until further evidence supports alternative metrics.
What it found20.4% and 34.1% of MASLD patients not obese by BMI met obesity criteria under EASO and Lancet definitions, but these groups had no higher liver-related event risk (aSHR 1.15 [0.64-2.08] for EASO; 0.75 [0.42-1.34] for Lancet) vs non-obese counterparts.
ContextChallenges the utility of newer obesity definitions (EASO, Lancet) for liver risk prediction in MASLD, confirming BMI remains the simpler and equally predictive metric in this cohort.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Cai J … VCTE-Prognosis Study Group · Hepatology · IF 18.0 · PubMed ↗Permalink
← Read the whole of issue №4 Every paper GI Signals surfaces gets a page like this one. All issues